Sarepta Therapeutics’ expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market.
— Read on www.marketbeat.com/originals/sarepta-therapeutics-stock-soars-on-fda-approval/
Sarepta Therapeutics’ expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market.
— Read on www.marketbeat.com/originals/sarepta-therapeutics-stock-soars-on-fda-approval/